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1.1 PLENARY SPEAKER
THE IDGHS (f~IH)AND LOWS (13ld OF HUMAN HEART 13rADRENOCEPTORS (AR). P Molenaar (1,2),
P Klenowski (2), AB Semmler (2), K Chee (2), M Iconomou (2), N Tugiono (3), H Kiriazis (3), 0 Xu (3). XJ Du
(3). U Ravens (4). T Christ (4) & A Kaumann (5) (1) Department of Medicine. Univ ofOueensland, Old 4032, (2)
Institute of Health and Biomedical Innovation, OUT, Old 4059, (3) BakerIDI Heart and Diabetes Institute, Vic
3004, (4) Department of Pharmacology and Toxicology, Dresden Univ of Technology, Germany & (5)
Department of Physiology, Development and Neuroscience, Univ of Cambridge, Cambridge, UK
The ~IAR has two binding sites which can be activated to cause cardiostimulation. The first, termed, ~IHAR (high
affinity site ~IAR) is activated by noradrenaline and adrenaline and is blocked by relatively low concentrations of
P-blockers including carvedilol. The other, termed, ~ILAR (low affinity site ~IAR) has lower affmity for
adrenaline and noradrenaline and is activated by some P-blockers including CGP12177 and pindolol at higher
concentrations than those required to block the receptor. (-)-CGP 12177 is a non-conventional partial agonist that
causes modest and transient increases of contractile force in human atrial trabeculae. These effects are markedly
increased and maintained by inhibition of phosphodiesterase PDE3. The stimulant effects of (-)-CGP12177 at
human ~IARs were verified with recombinant receptors (Kaumann and Molenaar, 2008). However, Skeberdis et
al (2008) proposed that the positive inotropic effects of CGP12177 are mediated through ~3ARs in human right
atrium. This proposal was not consistent with the lack of blockade of (-)-CGP 12177 inotropic effects or increases
in L-type Ca2+ current (ICa-L) by the P3AR blocker LY748,337 (1 )lM, Christ et aI, 2010). In contrast, (-)-
CGP12177-evoked increases in inotropic effects and ICa-L were blocked by (-)-bupranolol1-10 )lM (Christ et aI,
2010). Chronic infusion of (-)-CGP12177 (10 mglKg/24 hours) for 4 weeks in a mouse model ofleft ventricular
hypertrophy induced by aortic constriction caused increases in ventricular wall thickness, fibrosis- and
inflammation-related gene expression levels. ~-Blockers with cardiostimulant effects mediated through ~ILAR
could potentially be harmful in cardiac disease.
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